COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06ORI
|
|||
Drug Name |
Ketamine
|
|||
Synonyms |
ketamine; Ketaject; Ketalar; dl-Ketamine; CI 581 base; Special K; (+-)-Ketamine; Ketaminum; CLSTA 20; Ketanest; Ketalar base; 6740-88-1; (+/-)-Ketamine; KETAMINE HCL; Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; Special K [street name]; NSC 70151; EINECS 229-804-1; CHEMBL742; BRN 2216965; CHEBI:6121; YQEZLKZALYSWHR-; Ketamine
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Anaesthesia | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C13H16ClNO
|
|||
Canonical SMILES |
CNC1(CCCCC1=O)C2=CC=CC=C2Cl
|
|||
InChI |
1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
|
|||
InChIKey |
YQEZLKZALYSWHR-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 6740-88-1
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:6121
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076092. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.